Translational & Clinical Research (TACR) Program

翻译和临床研究 项目总结/摘要 转化和临床研究（TACR）计划成立于2016年初，是一个前瞻性的， 积极应对转化和临床癌症研究从以疾病为中心的 范式，并走向跨疾病的网站创新和发展。TACR代表了 基础科学计划和临床为基础的，疾病特异性研究小组，旨在加快 翻译密歇根大学综合癌症中心开发的创新临床方法 （UMCCC）研究人员到诊所。该计划由来自24个不同部门的69名成员组成 代表6所不同的学校和大学2016年，TACR成员每年的总收入为2880万美元（DC） 癌症补助资金，其中700万美元（24.3%）来自NCI，270万美元（9.4%）来自其他NIH，1260万美元（43.7%）， 都是经过同行评审的此外，TACR成员还得到药品和器械公司的赠款 总资金为1450万美元（50.4%）。研究人员参与项目内和项目间的互动， 积极与其他UMCCC项目的研究人员合作，在大多数基础科学和癌症领域 控制和人口科学计划。会员共有出版物1423种，其中31.1%为 50.6%为方案内，50.6%为方案间。TACR计划有三个主要的具体目标：I）使用 最先进的基因组学方法，以促进患者护理的发现; II）推进新型UMCCC 概念和代理人进入人体试验，以加快实验室发现转化为临床;和III） 开发和测试新的预测生物标志物和疾病监测策略，以改善患者护理。

TRANSLATIONAL AND CLINICAL RESEARCH PROJECT SUMMARY/ABSTRACT The Translational and Clinical Research (TACR) Program was established in early 2016 as a forward-looking, proactive response to an ongoing shift in translational and clinical cancer research away from disease-centric paradigms, and toward cross-disease site innovation and development. TACR represents the interface between basic science Programs and the clinic-based, disease-specific research groups and is designed to expedite the translation of innovative clinical approaches developed by University of Michigan Comprehensive Cancer Center (UMCCC) researchers to the clinic. The program is comprised of 69 members from 24 different departments representing 6 different schools and colleges. In 2016, TACR members had a total of $28.8M in annual (DC) cancer grant funding, of which $7M (24.3%) is from NCI, $2.7M (9.4%) is from other NIH, and $12.6M (43.7%), is total peer-reviewed. In addition, TACR members are supported by grants from drug and device companies with total funding of $14.5M (50.4%). Investigators are involved in intra- and inter-programmatic interactions and actively collaborate with researchers in the other UMCCC programs within most of the Basic Science and Cancer Control and Population Sciences Programs. Members have a total of 1423 publications, of which 31.1% are intra-programmatic and 50.6% are inter-programmatic. The TACR program has three main Specific Aims: I) use state-of-the-art genomic approaches to make discoveries that advance patient care; II) Advance novel UMCCC concepts and agents into human trials to expedite the translation of laboratory discoveries to the clinic; and III) Develop and test new predictive biomarker and disease monitoring strategies for improving patient care.